Search Site   
News Stories at a Glance
CGB breaks ground on Ports of Indiana expansion project
Ohio Farm Bureau hosts Ag events for kids in 4 counties
Solar grazing on the rise on Indiana farms
Late-season nitrogen may improve soybean meal used in livestock feed
Lack of broadband funds from BEAD could impact  Illinois farmers
New invasive Asian copperleaf weed detected in Illinois fields
Farmers need to understand farm water usage prior to data center talks
2026 World Pork Expo just around the corner at Iowa State Fairgrounds
Ohio Wine Producers Association launches Thyme for Wine Herb Trail experience
Mounted archery takes aim at Rising Glory Farm
Significant rain, coupled with cool weather, slows Midwest fieldwork
   
Archive
Search Archive  
   

FDA taking comments again on proposed gluten-free rule

By MICHELE F. MIHALJEVICH
Indiana Correspondent

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) is reopening the comment period on its proposal to label gluten-free foods, the agency said last week.

Under the proposal, first announced in 2007, foods with gluten levels at or above 20 parts per million wouldn’t be allowed to be labeled as gluten-free. The labels of gluten-free foods would contain the phrase “prohibited grains.”

Earlier this year, several milling, baking and grain organizations wrote a letter to the FDA asking officials to reconsider and to use the phrase “gluten-containing grains” instead.

“There are numerous misperceptions about gluten and we do not want to fuel those unjustified claims that going gluten-free can help with weight loss, autism, ADD, MS, etc.,” the letter stated.
Gluten is a protein found in wheat, rye and barley. People with celiac disease cannot tolerate gluten, the FDA stated, adding about 1 percent of the U.S. population is estimated to have the disease.

The comment period started Aug. 3 and runs for 60 days. To make a comment electronically, go to www.regulations.gov and click on “submit a comment” on the top task bar, enter docket number FDA-2005-N-0404 in the “keyword” space and select “search.”

To submit comments by mail, write to: The Division of Dockets Management, HFA-305, FDA, 5630 Fishers Lane, Room 1061, Rockville, MD 20852. Include docket number FDA-2005-N-0404 on each page of written comments.

8/10/2011